Opinion: Purple Book Patent Listings Are Only a First Step
May 8, 2021
By: Ted Mathias and Aaron Savit, PhD
The Center for Biosimilars
Axinn partners Ted Mathias and associate Aaron Savit authored The Center for Biosimilars article, "Opinion: Purple Book Patent Listings Are Only a First Step."
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Stakeholders 25th Annual CYOC Career Development Conference
Sponsorship
Antitrust
American Investment Council’s General Counsel Day
Speaking Engagement
Antitrust
Informa 34th Annual Advanced EU Brussels Conference
Speaking Engagement
Antitrust
Kisaco Research Pharma and Biotech Patent Litigation Summit 2025
Speaking Engagement
Intellectual Property
GCR Live: Women in Antitrust 2025
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2025
Speaking Engagement
Litigation & Trials
Biosimilar Approval Pathway Changes Sponsors Need to Monitor
Media Mentions
Intellectual Property

